Molecular subtyping improves prognostication of Stage 2 colorectal cancer

BMC Cancer

Table 1 Tumour recurrence, metastasis and lymph-node invasion by post-operative stage and by Consensus Molecular Subtype

	LR %	Mets %	Mets + LR %	LM %	LN %
TNM1	0	11.3	11.3	9.4	0
TNM2	4.7	9.4	12.5	6.2	1.6
TNM3	6.7	31.4	32.4	20	97.1
TNM4	4.5	100	100	81.8	86.4
P-value	0.2407	< 0.0001	< 0.0001	< 0.0001	< 0.0001
CMS1	3.3	11.7	13.3	3.3	25
CMS2	4.1	26.2	26.9	21.4	37.9
CMS3	5.3	13.2	18.4	7.9	44.7
CMS4	0	41.2	41.2	29.4	64.7
P-value*	0.9061	0.0211	0.0479	0.0009	0.0171

Tumour recurrence, metastasis and lymph-node invasion by Consensus Molecular Subtype (CMS) and by tumour-node-metastasis (TNM) stage given as percentages. P-value* is derived from analysis of classified tumours only and a P-value of < 0.05 is considered significant; LR Local recurrence, Mets, distant metastasis, diagnosed either at surgery or during the follow-up period; Mets + LR, local recurrence and distant metastasis combined; LM Liver metastasis, LN Lymph-node positive

ISSN: 1471-2407